|
1
|
Wang F, Chen G, Zhang Z, Yuan Y, Wang Y,
Gao YH, Sheng W, Wang Z, Li X, Yuan X, et al: The Chinese society
of clinical oncology (CSCO): Clinical guidelines for the diagnosis
and treatment of colorectal cancer, 2024 update. Cancer Commun
(Lond). 45:332–379. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hao VDT, Tri PM, My DT, Anh LT, Trung LV,
Bac NH and Vuong NL: FOLFOXIRI for first-line treatment of
unresectable colorectal cancer with liver metastases in a
resource-limited setting. J Gastrointest Cancer.
56(12)2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sebag-Montefiore D, Stephens RJ, Steele R,
Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint
AS, et al: Preoperative radiotherapy versus selective postoperative
chemoradiotherapy in patients with rectal cancer (MRC CR07 and
NCIC-CTG C016): A multicentre, randomised trial. Lancet.
373:811–820. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xiao BY, Zhang X, Cao TY, Li DD, Jiang W,
Kong LH, Tang JH, Han K, Zhang CZ, Mei WJ, et al: Neoadjuvant
immunotherapy leads to major response and low recurrence in
localized mismatch repair-deficient colorectal cancer. J Natl Compr
Cancer Netw. 21:60–66. 2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guo KC, Wang ZZ and Su XQ: Chinese
medicine in colorectal cancer treatment: From potential targets and
mechanisms to clinical application. Chin J Integr Med: Sep 27, 2024
(Epub ahead of print).
|
|
6
|
Jiang Y, Wang C, Zu C, Rong X, Yu Q and
Jiang J: Synergistic potential of nanomedicine in prostate cancer
immunotherapy: Breakthroughs and prospects. Int J Nanomedicine.
19:9459–9486. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Winawer SJ and Zauber AG: The advanced
adenoma as the primary target of screening. Gastrointest Endosc
Clin N Am. 12:1–9. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Edin S, Wikberg ML, Dahlin AM, Rutegård J,
Öberg Å, Oldenborg PA and Palmqvist R: The distribution of
macrophages with a M1 or M2 phenotype in relation to prognosis and
the molecular characteristics of colorectal cancer. PLoS One.
7(e47045)2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Khan SU, Khan MU, Din MA, Khan IM, Khan
MI, Bungau S and Hassan SSU: Reprogramming tumor-associated
macrophages as a unique approach to target tumor immunotherapy.
Front Immunol. 14(1166487)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bruni D, Angell HK and Galon J: The immune
contexture and Immunoscore in cancer prognosis and therapeutic
efficacy. Nat Rev Cancer. 20:662–680. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang H, Tian T and Zhang J:
Tumor-associated macrophages (TAMs) in colorectal cancer (CRC):
From mechanism to therapy and prognosis. Int J Mol Sci.
22(8470)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li J, Li L, Li Y, Long Y, Zhao Q, Ouyang
Y, Bao W and Gong K: Tumor-associated macrophage infiltration and
prognosis in colorectal cancer: Systematic review and
meta-analysis. Int J Colorectal Dis. 35:1203–1210. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wei C, Yang C, Wang S, Shi D, Zhang C, Lin
X, Liu Q, Dou R and Xiong B: Crosstalk between cancer cells and
tumor associated macrophages is required for mesenchymal
circulating tumor cell-mediated colorectal cancer metastasis. Mol
Cancer. 18(64)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Massague J and Ganesh K:
Metastasis-initiating cells and ecosystems. Cancer Discov.
11:971–994. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gao W, Chen L, Ma Z, Du Z, Zhao Z, Hu Z
and Li Q: Isolation and phenotypic characterization of colorectal
cancer stem cells with organ-specific metastatic potential.
Gastroenterology. 145:636–646. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fekir K, Dubois-Pot-Schneider H, Désert R,
Daniel Y, Glaise D, Rauch C, Morel F, Fromenty B, Musso O, Cabillic
F and Corlu A: Retrodifferentiation of human tumor hepatocytes to
stem cells leads to metabolic reprogramming and chemoresistance.
Cancer Res. 79:1869–1883. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nagata T, Sakakura C, Komiyama S,
Miyashita A, Nishio M, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y,
Ikoma H, et al: Expression of cancer stem cell markers CD133 and
CD44 in locoregional recurrence of rectal cancer. Anticancer Res.
31:495–500. 2011.PubMed/NCBI
|
|
21
|
Miranda A, Hamilton PT, Zhang AW, Pattnaik
S, Becht E, Mezheyeuski A, Bruun J, Micke P, de Reynies A and
Nelson BH: Cancer stemness, intratumoral heterogeneity, and immune
response across cancers. Proc Natl Acad Sci USA. 116:9020–9029.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Luo S, Yang G, Ye P, Cao N, Chi X, Yang WH
and Yan X: Macrophages are a double-edged sword: Molecular
crosstalk between tumor-associated macrophages and cancer stem
cells. Biomolecules. 12(850)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sato T, Takagi K, Higuchi M, Abe H,
Kojimahara M, Sagawa M, Tanaki M, Miki Y, Suzuki T and Hojo H:
Immunolocalization of CD80 and CD86 in non-small cell lung
carcinoma: CD80 as a potent prognostic factor. Acta Histochem
Cytochem. 55:25–35. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Murar M and Vaidya A: Cancer stem cell
markers: Premises and prospects. Biomark Med. 9:1331–1342.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Schreuders EH, Ruco A, Rabeneck L, Schoen
RE, Sung JJ, Young GP and Kuipers EJ: Colorectal cancer screening:
A global overview of existing programmes. Gut. 64:1637–1649.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Basak D, Uddin MN and Hancock J: The role
of oxidative stress and its counteractive utility in colorectal
cancer (CRC). Cancers (Basel). 12(3336)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
DeDecker L, Coppedge B, Avelar-Barragan J,
Karnes W and Whiteson K: Microbiome distinctions between the CRC
carcinogenic pathways. Gut Microbes. 13(1854641)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang
X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al: Periostin
secreted by glioblastoma stem cells recruits M2 tumour-associated
macrophages and promotes malignant growth. Nat Cell Biol.
17:170–182. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Clara JA, Monge C, Yang Y and Takebe N:
Targeting signalling pathways and the immune microenvironment of
cancer stem cells-a clinical update. Nat Rev Clin Oncol.
17:204–232. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xu J, Lin H, Wu G, Zhu M and Li M: .:
IL-6/STAT3 is a promising therapeutic target for hepatocellular
carcinoma. Front Oncol. 11(760971)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fasano M, Pirozzi M, Miceli CC, Cocule M,
Caraglia M, Boccellino M, Vitale P, De Falco V, Farese S, Zotta A,
et al: TGF-β modulated pathways in colorectal cancer: New potential
therapeutic opportunities. Int J Mol Sci. 25(7400)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cornice J, Verzella D, Arboretto P,
Vecchiotti D, Capece D, Zazzeroni F and Franzoso G: NF-κB:
Governing macrophages in cancer. Genes (Basel).
15(197)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wan S, Zhao E, Kryczek I, Vatan L,
Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH:
Tumor-associated macrophages produce interleukin 6 and signal via
STAT3 to promote expansion of human hepatocellular carcinoma stem
cells. Gastroenterology. 147:1393–1404. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lu H, Clauser KR, Tam WL, Fröse J, Ye X,
Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA and
Weinberg RA: A breast cancer stem cell niche supported by
juxtacrine signalling from monocytes and macrophages. Nat Cell
Biol. 16:1105–1117. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Aytekin EC, Unal B, Bassorgun CI and Ozkan
O: Clinicopathologic evaluation of CD80, CD86, and PD-L1
expressions with immunohistochemical methods in malignant melanoma
patients. Turk Patoloji Derg. 40:16–26. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kinouchi M, Miura K, Mizoi T, Ishida K,
Fujibuchi W, Ando T, Yazaki N, Saito K, Shiiba K and Sasaki I:
Infiltration of CD14-positive macrophages at the invasive front
indicates a favorable prognosis in colorectal cancer patients with
lymph node metastasis. Hepatogastroenterology. 58:352–358.
2011.PubMed/NCBI
|
|
37
|
Beider K, Bitner H, Leiba M, Gutwein O,
Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A
and Nagler A: Multiple myeloma cells recruit tumor-supportive
macrophages through the CXCR4/CXCL12 axis and promote their
polarization toward the M2 phenotype. Oncotarget. 5:11283–11296.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jääskeläinen MM, Tumelius R, Hämäläinen K,
Rilla K, Oikari S, Rönkä A, Selander T, Mannermaa A, Tiainen S and
Auvinen P: High numbers of CD163+tumor-associated macrophages
predict poor prognosis in HER2+breast cancer. Cancers (Basel).
16(634)2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Molina OE, LaRue H, Simonyan D, Hovington
H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A and Fradet Y:
High infiltration of CD209+ dendritic cells and CD163+ macrophages
in the peritumor area of prostate cancer is predictive of late
adverse outcomes. Front Immunol. 14(1205266)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Xu G, Jiang L, Ye C, Qin G, Luo Z, Mo Y
and Chen J: The ratio of CD86+/CD163+macrophages predicts
postoperative recurrence in stage II-III colorectal cancer. Front
Immunol. 12(724429)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liu J, Deng Y, Liu Z, Li X, Zhang M, Yu X,
Liu T, Chen K and Li Z: Identification of genes associated with
prognosis and immunotherapy prediction in triple-negative breast
cancer via M1/M2 macrophage ratio. Medicina (Kaunas).
59(1285)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fattahi F, Zanjani LS, Vafaei S, Shams ZH,
Kiani J, Naseri M, Gheytanchi E and Madjd Z: Expressions of TWIST1
and CD105 markers in colorectal cancer patients and their
association with metastatic potential and prognosis. Diagn Pathol.
16(26)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Inagaki K, Kunisho S, Takigawa H, Yuge R,
Oka S, Tanaka S, Shimamoto F, Chayama K and Kitadai Y: Role of
tumor-associated macrophages at the invasive front in human
colorectal cancer progression. Cancer Sci. 112:2692–2704.
2021.PubMed/NCBI View Article : Google Scholar
|
